Ravasio, R., Cranmer, H., Kearns , I., Viti, R., & Corinti, S. (2022). Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor. AboutOpen, 9(1), 92–104. https://doi.org/10.33393/ao.2022.2450